DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Idarubicin |
DMM0XGL
|
Minor |
Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Idarubicin. |
Acute myeloid leukaemia [2A60]
|
[9] |
Aminophylline |
DML2NIB
|
Moderate |
Decreased metabolism of Nalidixic acid caused by Aminophylline mediated inhibition of CYP450 enzyme. |
Asthma [CA23]
|
[10] |
Temozolomide |
DMKECZD
|
Minor |
Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Temozolomide. |
Brain cancer [2A00]
|
[9] |
Ketoprofen |
DMRKXPT
|
Moderate |
Additive CNS depression effects by the combination of Nalidixic acid and Ketoprofen. |
Chronic pain [MG30]
|
[11] |
Capecitabine |
DMTS85L
|
Minor |
Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Capecitabine. |
Colorectal cancer [2B91]
|
[9] |
Mestranol |
DMG3F94
|
Moderate |
Decreased absorption of Nalidixic acid due to formation of complexes caused by Mestranol. |
Contraceptive management [QA21]
|
[12] |
Mycophenolic acid |
DMRBMAU
|
Moderate |
Altered absorption of Nalidixic acid due to GI flora changes caused by Mycophenolic acid. |
Crohn disease [DD70]
|
[13] |
Stiripentol |
DMMSDOY
|
Moderate |
Decreased metabolism of Nalidixic acid caused by Stiripentol mediated inhibition of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[14] |
Mefenamic acid |
DMK7HFI
|
Moderate |
Additive CNS stimulant effects by the combination of Nalidixic acid and Mefenamic acid. |
Female pelvic pain [GA34]
|
[11] |
Procarbazine |
DMIK367
|
Minor |
Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Procarbazine. |
Hodgkin lymphoma [2B30]
|
[9] |
Didanosine |
DMI2QPE
|
Moderate |
Decreased absorption of Nalidixic acid due to formation of complexes caused by Didanosine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[15] |
Bempedoic acid |
DM1CI9R
|
Major |
Increased risk of tendinitis/tendon rupture by the combination of Nalidixic acid and Bempedoic acid. |
Hyper-lipoproteinaemia [5C80]
|
[16] |
Quinapril |
DMR8H31
|
Moderate |
Decreased absorption of Nalidixic acid due to formation of complexes caused by Quinapril. |
Hypertension [BA00-BA04]
|
[14] |
Givosiran |
DM5PFIJ
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nalidixic acid and Givosiran. |
Inborn porphyrin/heme metabolism error [5C58]
|
[8] |
Probenecid |
DMMFWOJ
|
Moderate |
Decreased elimination of Nalidixic acid caused by Probenecid mediated competitive inhibition of renal tubular secretion. |
Inborn purine/pyrimidine/nucleotide metabolism error [5C55]
|
[17] |
Meclofenamic acid |
DM05FXR
|
Moderate |
Additive CNS stimulant effects by the combination of Nalidixic acid and Meclofenamic acid. |
Inflammatory spondyloarthritis [FA92]
|
[18] |
Ramelteon |
DM7IW9J
|
Moderate |
Decreased metabolism of Nalidixic acid caused by Ramelteon mediated inhibition of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[19] |
Melatonin |
DMKWFBT
|
Minor |
Decreased metabolism of Nalidixic acid caused by Melatonin mediated inhibition of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[8] |
Tasimelteon |
DMLOQ1V
|
Moderate |
Decreased metabolism of Nalidixic acid caused by Tasimelteon mediated inhibition of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[20] |
Iron |
DMAP8MV
|
Moderate |
Decreased absorption of Nalidixic acid due to formation of complexes caused by Iron. |
Iron deficiency anaemia [3A00]
|
[21] |
Polyethylene glycol |
DM4I1JP
|
Moderate |
Increased risk of lowers seizure threshold by the combination of Nalidixic acid and Polyethylene glycol. |
Irritable bowel syndrome [DD91]
|
[22] |
Alosetron |
DML2A03
|
Moderate |
Decreased metabolism of Nalidixic acid caused by Alosetron mediated inhibition of CYP450 enzyme. |
Irritable bowel syndrome [DD91]
|
[23] |
Lurbinectedin |
DMEFRTZ
|
Minor |
Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Lurbinectedin. |
Lung cancer [2C25]
|
[9] |
Fludarabine |
DMVRLT7
|
Minor |
Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Fludarabine. |
Malignant haematopoietic neoplasm [2B33]
|
[9] |
Mercaptopurine |
DMTM2IK
|
Minor |
Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Mercaptopurine. |
Mature B-cell lymphoma [2A85]
|
[9] |
Cytarabine |
DMZD5QR
|
Minor |
Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Cytarabine. |
Mature B-cell lymphoma [2A85]
|
[9] |
Ethinyl estradiol |
DMODJ40
|
Moderate |
Decreased absorption of Nalidixic acid due to formation of complexes caused by Ethinyl estradiol. |
Menopausal disorder [GA30]
|
[12] |
Lanthanum carbonate |
DMMJQSH
|
Moderate |
Decreased absorption of Nalidixic acid due to formation of complexes caused by Lanthanum carbonate. |
Mineral absorption/transport disorder [5C64]
|
[24] |
Deflazacort |
DMV0RNS
|
Major |
Increased risk of tendinitis/tendon rupture by the combination of Nalidixic acid and Deflazacort. |
Muscular dystrophy [8C70]
|
[25] |
Hydroxyurea |
DMOQVU9
|
Minor |
Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Hydroxyurea. |
Myeloproliferative neoplasm [2A20]
|
[9] |
Bupropion |
DM5PCS7
|
Major |
Increased risk of lowers seizure threshold by the combination of Nalidixic acid and Bupropion. |
Nicotine use disorder [6C4A]
|
[26] |
Naproxen |
DMZ5RGV
|
Moderate |
Additive CNS stimulant effects by the combination of Nalidixic acid and Naproxen. |
Osteoarthritis [FA00-FA05]
|
[11] |
Carboplatin |
DMG281S
|
Minor |
Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Carboplatin. |
Ovarian cancer [2C73]
|
[9] |
Topotecan |
DMP6G8T
|
Minor |
Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Topotecan. |
Ovarian cancer [2C73]
|
[9] |
Aspirin |
DM672AH
|
Moderate |
Additive CNS stimulant effects by the combination of Nalidixic acid and Aspirin. |
Pain [MG30-MG3Z]
|
[27] |
Diflunisal |
DM7EN8I
|
Moderate |
Additive CNS depression effects by the combination of Nalidixic acid and Diflunisal. |
Pain [MG30-MG3Z]
|
[11] |
Ibuprofen |
DM8VCBE
|
Moderate |
Additive CNS depression effects by the combination of Nalidixic acid and Ibuprofen. |
Pain [MG30-MG3Z]
|
[11] |
Rasagiline |
DM3WKQ4
|
Major |
Decreased metabolism of Nalidixic acid caused by Rasagiline mediated inhibition of CYP450 enzyme. |
Parkinsonism [8A00]
|
[8] |
Choline salicylate |
DM8P137
|
Moderate |
Additive CNS stimulant effects by the combination of Nalidixic acid and Choline salicylate. |
Postoperative inflammation [1A00-CA43]
|
[18] |
Salsalate |
DM13P4C
|
Moderate |
Additive CNS stimulant effects by the combination of Nalidixic acid and Salsalate. |
Rheumatoid arthritis [FA20]
|
[11] |
Meloxicam |
DM2AR7L
|
Moderate |
Additive CNS stimulant effects by the combination of Nalidixic acid and Meloxicam. |
Rheumatoid arthritis [FA20]
|
[11] |
Oxaprozin |
DM9UB0P
|
Moderate |
Additive CNS stimulant effects by the combination of Nalidixic acid and Oxaprozin. |
Rheumatoid arthritis [FA20]
|
[11] |
Dexamethasone |
DMMWZET
|
Major |
Increased risk of tendinitis/tendon rupture by the combination of Nalidixic acid and Dexamethasone. |
Rheumatoid arthritis [FA20]
|
[25] |
Asenapine |
DMSQZE2
|
Moderate |
Decreased metabolism of Nalidixic acid caused by Asenapine mediated inhibition of CYP450 enzyme. |
Schizophrenia [6A20]
|
[28] |
Dactinomycin |
DM2YGNW
|
Minor |
Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Dactinomycin. |
Solid tumour/cancer [2A00-2F9Z]
|
[9] |
Methylprednisolone |
DM4BDON
|
Major |
Increased risk of tendinitis/tendon rupture by the combination of Nalidixic acid and Methylprednisolone. |
Solid tumour/cancer [2A00-2F9Z]
|
[25] |
Docetaxel |
DMDI269
|
Minor |
Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Docetaxel. |
Solid tumour/cancer [2A00-2F9Z]
|
[9] |
Mitoxantrone |
DMM39BF
|
Minor |
Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Mitoxantrone. |
Solid tumour/cancer [2A00-2F9Z]
|
[9] |
Prednisolone |
DMQ8FR2
|
Major |
Increased risk of tendinitis/tendon rupture by the combination of Nalidixic acid and Prednisolone. |
Solid tumour/cancer [2A00-2F9Z]
|
[25] |
Taxol |
DMUOT9V
|
Minor |
Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Taxol. |
Solid tumour/cancer [2A00-2F9Z]
|
[9] |
Doxorubicin |
DMVP5YE
|
Minor |
Decreased absorption of Nalidixic acid due to intestinal mucosa variation caused by Doxorubicin. |
Solid tumour/cancer [2A00-2F9Z]
|
[9] |
Tacrolimus |
DMZ7XNQ
|
Moderate |
Increased risk of nephrotoxicity by the combination of Nalidixic acid and Tacrolimus. |
Transplant rejection [NE84]
|
[8] |
----------- |
|
|
|
|
|